Related Experiment Video
Updated: Jul 15, 2026
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Bcl-2 expression in rectal cancer
Paulo C Contu1, Simone S Contu, Luis F Moreira
1Post-graduate Programme in Surgery, Faculty of Medicine, Federal University of Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Arquivos De Gastroenterologia
|April 5, 2007
Summary
The anti-apoptotic protein bcl-2 was expressed in 29.5% of rectal adenocarcinoma cases, showing a higher prevalence in women. Its association with clinical outcomes requires further investigation for predicting therapeutic response.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Proteins regulating apoptosis are implicated in colorectal cancer development.
- Understanding bcl-2 protein's role is crucial for cancer research.
Purpose of the Study:
- To investigate the prevalence of bcl-2 protein expression in rectal adenocarcinoma.
- To correlate bcl-2 expression with clinical and histopathological features.
Main Methods:
- Immunohistochemical analysis of bcl-2 protein expression.
- Study included 132 patients with rectal adenocarcinoma.
Main Results:
- Bcl-2 protein expression was observed in 29.5% of cases.
- Higher bcl-2 prevalence was noted in female patients.
- No significant association found with age, grade, invasion, metastasis, or stage, though a trend suggested lower expression in poorly differentiated tumors.
Conclusions:
- Bcl-2 protein expression analysis may aid in predicting treatment response and prognosis in colorectal cancer.
- Further research is needed to determine the clinical utility of bcl-2 assessment in rectal cancer management.
